Author Archive for: panglobal

Neogap Therapeutics AB has been granted Chinese patent protecting its proprietary method for expanding tumour-specific T cells, marking a significant milestone in the company’s international intellectual property strategy. The patent, which provides legal protection until 2038, covers a core manufacturing process for the company’s personalised cell-based immunotherapy, pTTL, currently under evaluation in Phase I/II clinical […]

Nabsys 2.0, LLC presented data on its OhmX™ Platform at the American Society of Human Genetics (ASHG) Annual Meeting in Boston, Massachusetts, from 14-18 October 2025. The presentations demonstrated applications of electronic genome mapping (EGM) technology in multiple disease states, including interstitial cystitis/bladder pain syndrome, hematological malignancies, and repeat expansion disorders.

Celonic Group, a biologics contract development and manufacturing organisation based in Basel, Switzerland, has entered into a strategic alliance with CARBOGEN AMCIS to establish an end-to-end platform for antibody-drug conjugate (ADC) production. The collaboration combines Celonic’s upstream biologics capabilities with CARBOGEN AMCIS’s downstream expertise in payload synthesis, conjugation chemistry, and sterile fill-finish operations.

Polpharma Group, a major pharmaceutical manufacturer serving Central and Eastern Europe and Central Asia, has confirmed a planned leadership transition effective 1 January 2026. Markus Sieger will step down as chief executive officer after ten years of service, with Sebastian Szymanek succeeding him in the role.